| MOPEB06 | Liver fibrosis regression measured by transient elastography in people living with HIV successfully treated for hepatitis C using direct acting antivirals | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB07 | Early clinical experience using tecovirimat during the Mpox epidemic in Toronto suggests ongoing clinical equipoise for randomized trials | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB08 | Characterization of mpox in people who live with HIV: a country-wide observational study | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB09 | PEPFAR tuberculosis preventive treatment coverage and remaining gaps among people living with HIV | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB10 | Performance of rifampicin resistant TB regimens used as standard-care in the TB-PRACTECAL clinical trial | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB11 | Impact of HIV during standard first-line tuberculosis treatment on the risk of subsequent rifampicin-resistant TB in the Western Cape Province, South Africa | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB12 | Change in size-adjusted bone density by HIV status among peripubertal children in Zimbabwe: a prospective cohort study | Poster exhibition | Co-morbidities |
| MOPEB13 | Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV | Poster exhibition | Co-morbidities |
| MOPEB14 | Accuracy of a new PHQ-9 scoring algorithm to screen for depression in PLHIV cohorts in Sub-Saharan Africa | Poster exhibition | Co-morbidities |
| MOPEB15 | Bone mineral density changes in postpartum mothers living with HIV on antiretroviral therapy | Poster exhibition | Co-morbidities |